Responses
Poster Presentations
Bone diseases other than osteoporosis, metabolic diseases and crystal diseases
SAT0329 Lesinurad, A Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout: the Crystal Phase III Clinical Trial
Compose a Response to This Article
Other responses
No responses have been published for this article.